Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Quadrivalent Influenza Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Sponsor : Clover Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Clover gains commercial rights to AdimFlu-S (quadrivalent influenza vaccine) in mainland China, Bangladesh, Brazil and the Philippines. AdimFlu-S is a quadrivalent split inactivated vaccine intended for use in the preven...
Brand Name : AdimFlu-S
Molecule Type : Vaccine
Upfront Cash : Undisclosed
February 19, 2023
Lead Product(s) : Quadrivalent Influenza Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Sponsor : Clover Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Covid-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Recipient : Eden Biologics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the Master Service Agreement, JHL Biotech will support Adimmune Corporation to manufacture and supply the Antigen for their leading Covid-19 vaccine candidate.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
September 11, 2020
Lead Product(s) : Covid-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Recipient : Eden Biologics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Adimmune May Start COVID-19 Vaccine Clinical Trials in August
Details : Adimmune had designed and produced 4 prototypes of antigens to fight Covid-19 based on its recombinant protein technology, and has tested one prototype in a BSL-3 lab at National Taiwan University.
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Not Applicable
May 06, 2020
Lead Product(s) : COVID-19 vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?